Ironwood Pharmaceuticals (IRWD) 10.45 $IRWD
Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign
M2 - Fri Apr 11, 7:26AM CDT
US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS(R)
Business Wire - Thu Apr 10, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS(R) (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.
Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call
Business Wire - Tue Apr 08, 6:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2014 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2014. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 3733415. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Use Options For A Chance To Buy IRWD At A 31% Discount
at The Street - Wed Mar 19, 10:42AM CDT
Looking back to 36 days ago, Ironwood Pharmaceuticals Inc. priced a 13,725,500 share secondary stock offering at $12.75 per share.
Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Tue Mar 18, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
Research and Markets: Research and Forecast of China Antifreeze Market, 2014-2018
Business Wire - Tue Feb 25, 6:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/wq7dvj/research_and) has announced the addition of the "Research and Forecast of China Antifreeze Market, 2014-2018" report to their offering.
Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. Eastern Time at The Boston Marriott Copley Place.
Ironwood Pharmaceuticals Inc reports exercise of 2.059 Class A common stock in underwriters' option in public offering
M2 - Fri Feb 14, 3:27AM CST
Medicines company Ironwood Pharmaceuticals Inc (NasdaqGS:IRWD) said on Thursday that the underwriters of its public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares, at a public offering price of USD12.75 per share.
Ironwood Pharmaceuticals Announces Exercise of Underwriters' Option in Public Offering of Common Stock
Business Wire - Thu Feb 13, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its previously announced public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares at a public offering price of $12.75 per share. As a result, Ironwood will issue a total of 15,784,325 shares in the offering and will receive aggregate net proceeds, after underwriting discounts and commissions and other estimated offering expenses, of approximately $190.4 million. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
4 Stocks Breaking Out on Big Volume
at The Street - Thu Feb 13, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors
Business Wire - Wed Feb 12, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Julie McHugh to its board of directors. Ms. McHugh has served in leadership positions for both large pharmaceutical and small biotechnology businesses and brings to the Ironwood board significant experience in operations, strategy, product development and marketing.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Feb 11, 10:22PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of an underwritten public offering of 13,725,500 shares of its Class A common stock at a price of $12.75 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Feb 10, 3:04PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it has commenced a $150 million underwritten public offering of its Class A common stock. All of the shares are being offered by Ironwood. Ironwood will grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the number of shares of Class A common stock sold in the offering.
Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS(R) Patent Protection Through 2031
Business Wire - Mon Feb 10, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS(R) (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.
Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 1:50 p.m. Eastern Time at the Waldorf Astoria Hotel in New York.
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign
M2 - Fri Apr 11, 7:26AM CDT
US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS(R)
Business Wire - Thu Apr 10, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS(R) (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.
Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call
Business Wire - Tue Apr 08, 6:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2014 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2014. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 3733415. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Use Options For A Chance To Buy IRWD At A 31% Discount
at The Street - Wed Mar 19, 10:42AM CDT
Looking back to 36 days ago, Ironwood Pharmaceuticals Inc. priced a 13,725,500 share secondary stock offering at $12.75 per share.
Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Tue Mar 18, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
Research and Markets: Research and Forecast of China Antifreeze Market, 2014-2018
Business Wire - Tue Feb 25, 6:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/wq7dvj/research_and) has announced the addition of the "Research and Forecast of China Antifreeze Market, 2014-2018" report to their offering.
Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. Eastern Time at The Boston Marriott Copley Place.
Ironwood Pharmaceuticals Inc reports exercise of 2.059 Class A common stock in underwriters' option in public offering
M2 - Fri Feb 14, 3:27AM CST
Medicines company Ironwood Pharmaceuticals Inc (NasdaqGS:IRWD) said on Thursday that the underwriters of its public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares, at a public offering price of USD12.75 per share.
Ironwood Pharmaceuticals Announces Exercise of Underwriters' Option in Public Offering of Common Stock
Business Wire - Thu Feb 13, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its previously announced public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares at a public offering price of $12.75 per share. As a result, Ironwood will issue a total of 15,784,325 shares in the offering and will receive aggregate net proceeds, after underwriting discounts and commissions and other estimated offering expenses, of approximately $190.4 million. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
4 Stocks Breaking Out on Big Volume
at The Street - Thu Feb 13, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors
Business Wire - Wed Feb 12, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Julie McHugh to its board of directors. Ms. McHugh has served in leadership positions for both large pharmaceutical and small biotechnology businesses and brings to the Ironwood board significant experience in operations, strategy, product development and marketing.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Feb 11, 10:22PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of an underwritten public offering of 13,725,500 shares of its Class A common stock at a price of $12.75 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Feb 10, 3:04PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it has commenced a $150 million underwritten public offering of its Class A common stock. All of the shares are being offered by Ironwood. Ironwood will grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the number of shares of Class A common stock sold in the offering.
Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS(R) Patent Protection Through 2031
Business Wire - Mon Feb 10, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS(R) (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.
Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 1:50 p.m. Eastern Time at the Waldorf Astoria Hotel in New York.
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
